Serum sAPO-1/Fas levels in multiple sclerosis
- 1 April 1997
- journal article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 95 (4) , 208-210
- https://doi.org/10.1111/j.1600-0404.1997.tb00100.x
Abstract
Soluble APO-1 (sAPO-1) may prevent apoptosis of lymphocytes induced by activation of the APO-1/Fas receptor. Objectives – To determine sAPO-1 levels in the serum of multiple sclerosis (MS) patients and controls in order to investigate if abnormal lymphocyte apoptosis occurs in this disease. Methods – Serum samples from patients with MS, other neurological diseases, systemic lupus erythematosus and healthy controls were determined by enzyme-linked immunosorbent assay. Results – We did not detect differences in mean serum sAPO-1 levels between patients with multiple sclerosis and controls. Conclusions – This preliminary study suggests that resistance of peripheral blood lymphocytes to apoptosis mediated by sAPO-1 is not likely to be a major factor in the development of autoreactive cells in MS.Keywords
This publication has 4 references indexed in Scilit:
- Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas MoleculeScience, 1994
- The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosisCell, 1991
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983